Antoîne Italiano

Research interests

Publications

• Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02321-8

• ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.05.520

• Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00380-1

• Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

  The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00380-1

• Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

  Nature Cancer · 2021 · https://doi.org/10.1038/s43018-021-00232-6

• Sotorasib for Lung Cancers with KRAS p.G12C Mutation

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2103695

• Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE ‐158 and KEYNOTE ‐028 studies

  International Journal of Cancer · 2020 · https://doi.org/10.1002/ijc.33013

• Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30321-1

• Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30445-9

• B cells are associated with survival and immunotherapy response in sarcoma

  Nature · 2020 · https://doi.org/10.1038/s41586-019-1906-8

• Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30825-3

• Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30451-4

• Pazopanib or methotrexate–vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30276-1

• Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

  Clinical Cancer Research · 2019 · https://doi.org/10.1158/1078-0432.ccr-18-3334

• Surgery in reference centers improves survival of sarcoma patients: a nationwide study

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz124

• Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30144-x

• Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

  JAMA Oncology · 2017 · https://doi.org/10.1001/jamaoncol.2017.1617

• Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group

  European Journal of Cancer · 2017 · https://doi.org/10.1016/j.ejca.2017.06.017

• Improved survival using specialized multidisciplinary board in sarcoma patients

  Annals of Oncology · 2017 · https://doi.org/10.1093/annonc/mdx484

• Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

  The Lancet · 2016 · 10.1016/s0140-6736(15)01283-0

• Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30507-1

• Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France

  European Journal of Cancer · 2016 · https://doi.org/10.1016/j.ejca.2016.02.008

• Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)00075-9

• PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma

  Journal of Clinical Oncology · 2016 · https://doi.org/10.1200/jco.2016.67.6684

• Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1502309

• Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.60.7341

• Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

  Cancer Cell · 2014 · https://doi.org/10.1016/j.ccr.2014.05.016

• Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70474-6

Current projects

No projects listed.